The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
“(i) promote transparency, with the collaboration of the Member States, and, when appropriate, the dissemination of information useful for research and development and for research findings.”
Earlier blog: https://www.keionline.org/20920